Listed as number three in pharma sales, GlaxoSmithKline has had some rough luck thanks in part to the diabetes drug Avandia, which has been pulled out of Europe and restricted in the U.S after global side effect concerns since 2007. The company cut its losses on the drug, writing off $233 million in supplies and eliminating its marketing efforts of the drug.

The company has racked up some charges against its earnings, including over $6 billion in the fourth quarter of 2010 from Avandia and marketing settlements. GSK settled 10,000 Avandia lawsuits for a combined $460 million. Also, the company hit number three on FiercePharma's Top Layoffs of 2010 list with 5,201 jobs lost. While other companies look towards more spinoffs, GSK has focused on emerging markets as its ticket to higher revenue. It purchased Laboratorios Phoenix in 2009 and China's MeiRui in 2010; the UK-based company said the impact of its layoffs would be masked by more job opportunities in Asia and South America.

In early 2011, GSK and Human Genome Sciences gained FDA approval for Benlysta, the first new lupus treatment in more than 50 years, and experts believe it could be a $3 billion to $5 billion worldwide sales heyday for the partnership. But the FDA denied an extended approval and a potential $1 billion in sales to GSK from the prostate drug Avodart. While the drug was effective against low-risk malignant tumors, it potentially heightened the risk of developing more aggressive tumors.

GSK spun off its HIV treatments into ViiV Healthcare in 2009, combining it with Pfizer's former R&D efforts in the field. ViiV markets Ziagen, Trizivir, Epzicom and abacavir as part of its suite of drugs for HIV/AIDS.



Latest Headlines

Latest Headlines

Study finds some docs are not strongly recommending HPV vaccines for preteens

Merck and GlaxoSmithKline have spent years working to build the market for their HPV vaccines, and a new study may demonstrate one factor that has hindered their efforts.

Witty builds case for why 2016 is GSK's pivotal year

2016 is the year that GlaxoSmithKline is supposed to start to show the results of CEO Andrew Witty's turnaround efforts. Well 2016 is here and Witty is expected to show up at the JP Morgan Healthcare Conference next week with plans he hopes will convince investors that his efforts to remake the British pharma giant have not been in vain.

GSK's new $32,500 asthma med costs at least 2X too much, U.S. pricing watchdog says

GlaxoSmithKline has a new drug that's tailored for patients with a specific type of severe asthma. But according to a nonprofit body that evaluates drugs' prices against their clinical effectiveness, it costs far, far too much.

GSK adds Bristol-Myers pipeline drugs to challenge Gilead in HIV

It wasn't all that long ago that GlaxoSmithKline was considering a spinoff for its HIV drugs division, ViiV Healthcare. Now, though, the company is hanging on tight to that business--and building it up, too.

GlaxoSmithKline launched new e-commerce platform for vaccines, pharma products

In March, GlaxoSmithKline and Novartis completed their $7.1 billion asset swap that was nearly a year in the making. The deal saw the British pharma bolster its vaccine business as it traded away its oncology unit for Novartis' vaccines business. Now, Glaxo is officially announcing the launch of GSKDirect, a new e-commerce platform that simplifies the way customers order vaccines and pharmaceutical products from the company.

Bristol-Myers flips its HIV pipeline to GlaxoSmithKline's ViiV in a $3B deal

Bristol-Myers Squibb is getting out of HIV R&D, selling its pipeline to the GlaxoSmithKline-controlled ViiV Healthcare in a transaction worth as much as $3 billion.

GSK's Avandia is free and clear at the FDA, 8 years after heart-safety controversy began

The FDA has lifted the final layer of safety measures on the GlaxoSmithKline diabetes drug Avandia, 8 years after researchers flagged an apparent increase in the risk of heart attack, and at least three years too late to make a difference in sales. The safety questions drove Avandia revenues down from a peak of $3 billion before the controversy to $183 million in 2011, just before generics hit the market.

GlaxoSmithKline and J&J march toward the FDA with a new arthritis treatment

Partners GlaxoSmithKline and Johnson & Johnson posted positive Phase III results for an injected treatment for rheumatoid arthritis, plotting to submit the therapy for global approvals next year.

FDA expands male age indication for Merck's Gardasil 9

One month after a European safety review raised no issues with the blockbuster-to-be HPV vaccine Gardasil 9, Merck received another boost for its jab this week.

GSK partners with Australian scientists to make cheaper pediatric vaccines

GlaxoSmithKline is teaming up with researchers from Monash University in Melbourne, Australia, to develop new manufacturing methods to make vaccines cheaper for children in the developing world.